Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Diabetes

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 125 articles:
HTML format



Single Articles


    July 2021
  1. RAJAGOPAL S, Cheskin LJ
    In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders.
    Ann Intern Med. 2021 Jul 6. doi: 10.7326/ACPJ202107200.
    PubMed     Abstract available


    June 2021
  2. SZAREK M, Bhatt DL, Steg PG, Cannon CP, et al
    Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
    Ann Intern Med. 2021 Jun 22. doi: 10.7326/M21-0651.
    PubMed     Abstract available


  3. CENTOR RM, Tuttle KR, Himmelfarb J
    Annals On Call - SGLT-2 Revisited: Diabetes Management in Chronic Kidney Disease.
    Ann Intern Med. 2021 Jun 1. doi: 10.7326/A20-0014.
    PubMed    


  4. TANNER M
    In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs.
    Ann Intern Med. 2021 Jun 1. doi: 10.7326/ACPJ202106150.
    PubMed     Abstract available


    May 2021

  5. Correction: Type 2 Diabetes.
    Ann Intern Med. 2021;174:735.
    PubMed    


    March 2021
  6. KARAGIANNIS T, Tsapas A, Bekiari E
    KDIGO made 12 recommendations for managing diabetes with CKD.
    Ann Intern Med. 2021 Mar 2. doi: 10.7326/ACPJ202103160.
    PubMed     Abstract available


  7. GRIFFIN TP, Dinneen SF
    In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia.
    Ann Intern Med. 2021;174:JC34.
    PubMed     Abstract available


    February 2021
  8. SMETANA GW, Tetrault JM, Hill KP, Burns RB, et al
    Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-7945.
    PubMed     Abstract available


    January 2021
  9. GREGORY JM, Moore DJ
    The Dual Burden of Type 1 Diabetes and COVID-19.
    Ann Intern Med. 2021 Jan 26. doi: 10.7326/M21-0367.
    PubMed    


  10. KABADI UM
    Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
    Ann Intern Med. 2021;174:140.
    PubMed    


  11. TSAPAS A, Karagiannis T, Avgerinos I, Matthews DR, et al
    Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
    Ann Intern Med. 2021;174:141.
    PubMed    


  12. HAO Q, Guyatt G
    Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.
    Ann Intern Med. 2021;174:JC10.
    PubMed     Abstract available


  13. HAO Q, Guyatt G
    Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.
    Ann Intern Med. 2021;174:JC11.
    PubMed     Abstract available


  14. KIM NH, Siddiqui M, Vogel J
    MELAS Syndrome and MIDD Unmasked by Metformin Use: A Case Report.
    Ann Intern Med. 2021;174:124-125.
    PubMed    


    December 2020
  15. LIAKOS A, Tsapas A, Bekiari E
    In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.
    Ann Intern Med. 2020;173:JC70.
    PubMed     Abstract available


  16. HICKS CW, Wang D, Matsushita K, Windham BG, et al
    Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults : A Prospective Cohort Study.
    Ann Intern Med. 2020 Dec 8. doi: 10.7326/M20-1340.
    PubMed     Abstract available


    November 2020
  17. GANDHI GY
    In type 2 diabetes, some glucose-lowering drugs reduce HbA1c more than others; drugs do not differ for mortality.
    Ann Intern Med. 2020;173:JC53.
    PubMed     Abstract available


  18. TANNER M
    In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA1c and SBP and may reduce body weight.
    Ann Intern Med. 2020;173:JC52.
    PubMed     Abstract available


  19. OLSON DE
    In older adults with type 1 diabetes, continuous glucose monitoring reduced hypoglycemia over 6 months.
    Ann Intern Med. 2020;173:JC54.
    PubMed     Abstract available


  20. PALASKAS NL, Deswal A
    In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization.
    Ann Intern Med. 2020;173:JC51.
    PubMed     Abstract available


  21. NAVANEETHAN SD, Zoungas S, Caramori ML, Chan JCN, et al
    Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline.
    Ann Intern Med. 2020 Nov 10. doi: 10.7326/M20-5938.
    PubMed     Abstract available


  22. DOUMOURAS AG, Hong D, Lee Y, Tarride JE, et al
    Association Between Bariatric Surgery and All-Cause Mortality: A Population-Based Matched Cohort Study in a Universal Health Care System.
    Ann Intern Med. 2020;173:694-703.
    PubMed     Abstract available


    October 2020
  23. GRIFFIN TP, Dinneen SF
    SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.
    Ann Intern Med. 2020;173:JC40.
    PubMed     Abstract available


  24. BRAILOVSKI E, Kim RB, Juurlink D
    Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report.
    Ann Intern Med. 2020;173:585-587.
    PubMed    


    September 2020

  25. Correction: Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
    Ann Intern Med. 2020;173:508.
    PubMed    


  26. YOSHIDA K, Sakamoto N, Kurosaka D
    Improvement in Polymyalgia Rheumatica Associated With Improved Control of Diabetes Mellitus: A Case Series.
    Ann Intern Med. 2020 Sep 15. doi: 10.7326/L20-0196.
    PubMed    


  27. DOYLE-DELGADO K, Chamberlain JJ, Shubrook JH, Skolnik N, et al
    Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline.
    Ann Intern Med. 2020 Sep 1. doi: 10.7326/M20-2470.
    PubMed     Abstract available


  28. VUKOTIC R, Raimondi F, Brodosi L, Vitale G, et al
    The Effect of Liraglutide on beta-Blockade for Preventing Variceal Bleeding: A Case Series.
    Ann Intern Med. 2020;173:404-405.
    PubMed    


    August 2020
  29. TARTOF SY, Qian L, Hong V, Wei R, et al
    Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization.
    Ann Intern Med. 2020 Aug 12. doi: 10.7326/M20-3742.
    PubMed     Abstract available


    July 2020
  30. DOUROS A, Lix LM, Fralick M, Dell'Aniello S, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study.
    Ann Intern Med. 2020 Jul 28. doi: 10.7326/M20-0289.
    PubMed     Abstract available


  31. LOOMIS E, Bajwa J, Kaizuka S
    Buprenorphine-Naloxone as a Novel Treatment of Narcotic Bowel Syndrome: A Case Report.
    Ann Intern Med. 2020;173:164-166.
    PubMed    


    June 2020
  32. LEE CG, Cefalu WT
    The Right Diabetes Medication for the Right Patient for the Right Outcome: Can a Network Meta-analysis Help Us Decide?
    Ann Intern Med. 2020 Jun 30. doi: 10.7326/M20-4266.
    PubMed    


  33. TSAPAS A, Avgerinos I, Karagiannis T, Malandris K, et al
    Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Ann Intern Med. 2020 Jun 30. doi: 10.7326/M20-0864.
    PubMed     Abstract available


    May 2020
  34. TIAN S, Wu J, Liu JS, Zou BS, et al
    Type 2 Diabetes.
    Ann Intern Med. 2020;172:704-705.
    PubMed    


  35. VIJAN S
    Type 2 Diabetes.
    Ann Intern Med. 2020;172:705.
    PubMed    



  36. Correction: In the Clinic: Type 2 Diabetes.
    Ann Intern Med. 2020;172:708.
    PubMed    


    April 2020
  37. TANNER M
    In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years.
    Ann Intern Med. 2020;172:JC41.
    PubMed    


  38. CHARI ST, Sharma A, Maitra A
    Early Detection of Sporadic Pancreatic Ductal Adenocarcinoma: Problems, Promise, and Prospects.
    Ann Intern Med. 2020;172:558-559.
    PubMed    


    March 2020
  39. KLOECKER DE, Davies MJ, Khunti K, Zaccardi F, et al
    Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.
    Ann Intern Med. 2020 Mar 24. pii: 2763641. doi: 10.7326/M19-3286.
    PubMed     Abstract available


  40. LIAKOS A, Liakopoulou P, Tsapas A
    Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers.
    Ann Intern Med. 2020;172:JC27.
    PubMed    


    February 2020
  41. BROWN K, Donato AA
    In type 2 diabetes, early metformin plus vildagliptin reduced treatment failure vs a stepwise approach.
    Ann Intern Med. 2020;172:JC23.
    PubMed    


  42. AI NG SY, Zhu D, Herrington WG
    In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes.
    Ann Intern Med. 2020;172:JC18.
    PubMed    


    January 2020
  43. RACO DL
    In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding.
    Ann Intern Med. 2020;172:JC4.
    PubMed    


  44. FRALICK M, Chen SK, Patorno E, Kim SC, et al
    Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
    Ann Intern Med. 2020 Jan 14. pii: 2758844. doi: 10.7326/M19-2610.
    PubMed     Abstract available


    December 2019
  45. DAVE CV, Schneeweiss S, Kim D, Fralick M, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.
    Ann Intern Med. 2019;171:944-945.
    PubMed    


  46. SARAFIDIS P, Papagianni A
    Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.
    Ann Intern Med. 2019;171:943-944.
    PubMed    


  47. BENJAMIN T, Schumacher C
    Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.
    Ann Intern Med. 2019;171:944.
    PubMed    


  48. CENTOR RM, Ovalle F
    Web Exclusive. Annals On Call - Technology to Improve Diabetes Management.
    Ann Intern Med. 2019;171:OC1.
    PubMed    


    November 2019
  49. VIJAN S
    Type 2 Diabetes.
    Ann Intern Med. 2019;171:ITC65-ITC80.
    PubMed     Abstract available


    October 2019
  50. MOIST L
    Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD.
    Ann Intern Med. 2019;171:JC43.
    PubMed    


  51. SMETANA GW, Nathan DM, Dugdale DC, Burns RB, et al
    To What Target Hemoglobin A1c Level Would You Treat This Patient With Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2019;171:505-513.
    PubMed     Abstract available


    September 2019
  52. SANTULLI G
    In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years.
    Ann Intern Med. 2019;171:JC31.
    PubMed    


  53. EL KAWKGI OM, Montori VM
    In high-risk type 1 diabetes, insulin pumps with suspend-before-low technology reduced hypoglycemic events.
    Ann Intern Med. 2019;171:JC30.
    PubMed    


  54. LIPSCOMBE LL
    In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.
    Ann Intern Med. 2019;171:JC29.
    PubMed    


  55. LIPSCOMBE LL
    In patients >/= 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
    Ann Intern Med. 2019;171:JC28.
    PubMed    


  56. LIPSCOMBE LL
    In patients >/= 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.
    Ann Intern Med. 2019;171:JC27.
    PubMed    


    August 2019
  57. GOEL A
    In type 2 diabetes, a primary care-led weight management program increased weight loss and diabetes remission at 2 years.
    Ann Intern Med. 2019;171:JC17.
    PubMed    


  58. LIPSCOMBE LL
    In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
    Ann Intern Med. 2019;171:JC16.
    PubMed    


  59. PATEL T
    Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease.
    Ann Intern Med. 2019;171:JC15.
    PubMed    


  60. CHAMBERLAIN JJ, Doyle-Delgado K, Peterson L, Skolnik N, et al
    Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2019 Aug 13. pii: 2748278. doi: 10.7326/M19-1638.
    PubMed     Abstract available


  61. WHARAM JF, Newhouse JP
    High-Deductible Insurance and Delay in Care.
    Ann Intern Med. 2019;171:226.
    PubMed    


  62. GOULET M, Goldstein J
    High-Deductible Insurance and Delay in Care.
    Ann Intern Med. 2019;171:226.
    PubMed    


    July 2019
  63. FILION KB, Yu OH
    Sodium-Glucose Cotransporter-2 Inhibitors and Severe Urinary Tract Infections: Reassuring Real-World Evidence.
    Ann Intern Med. 2019 Jul 30. pii: 2739787. doi: 10.7326/M19-1950.
    PubMed    


  64. JACKSON GL, Smith VA, Edelman D, Hendrix CC, et al
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:145.
    PubMed    


  65. KUMAR PD
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:144.
    PubMed    


  66. GROTE J
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:144-145.
    PubMed    


  67. KE C, Shah BR, Stukel TA, Chan JCN, et al
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes.
    Ann Intern Med. 2019;171:78-79.
    PubMed    


  68. FINUCANE TE
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes.
    Ann Intern Med. 2019;171:78.
    PubMed    


    May 2019
  69. MERLI GJ, Weitz HH
    Web Exclusive. Annals Consult Guys - Cardiovascular Risk, Blood Pressure, and Cognition in a Patient With Diabetes.
    Ann Intern Med. 2019;170:CG1.
    PubMed    


  70. GOEL A
    Review: Viscous fiber reduces HbA1c, fasting glucose, and insulin resistance in type 2 diabetes.
    Ann Intern Med. 2019;170:JC51.
    PubMed    


    April 2019
  71. LUDVIGSSON JF, Neovius M, Soderling J, Gudbjornsdottir S, et al
    Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study.
    Ann Intern Med. 2019 Apr 23. pii: 2731602. doi: 10.7326/M18-1974.
    PubMed     Abstract available


  72. APOLZAN JW, Venditti EM, Edelstein SL, Knowler WC, et al
    Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
    Ann Intern Med. 2019 Apr 23. pii: 2731601. doi: 10.7326/M18-1605.
    PubMed     Abstract available


  73. KANSAGARA D, Humphrey LL, Qaseem A
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification.
    Ann Intern Med. 2019;170:583-584.
    PubMed    


  74. GOOD CB, Kolb NR, Meyer M
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification.
    Ann Intern Med. 2019;170:583.
    PubMed    


  75. PUNTHAKEE Z
    In type 2 diabetes with periodontitis, intensive periodontitis treatment improved glycemic control at 1 year.
    Ann Intern Med. 2019;170:JC40.
    PubMed    


  76. DAVIDSON MB
    Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes.
    Ann Intern Med. 2019;170:JC39.
    PubMed    


  77. ARTERBURN D
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:507-508.
    PubMed    


  78. KWON Y, Park S
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:507.
    PubMed    


  79. CARLSSON L, Carlsson B, Peltonen M
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:506-507.
    PubMed    


    January 2019
  80. KE C, Lau E, Shah BR, Stukel TA, et al
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes: A Population-Based Cohort Study.
    Ann Intern Med. 2019 Jan 15. pii: 2720956. doi: 10.7326/M18-1900.
    PubMed     Abstract available


    December 2018

  81. Correction: Glycemic Targets for Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2018;169:899.
    PubMed    


  82. SANTULLI G
    In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years.
    Ann Intern Med. 2018;169:JC67.
    PubMed    


    November 2018
  83. JACKSON GL, Smith VA, Edelman D, Woolson SL, et al
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants: A Cohort Study.
    Ann Intern Med. 2018 Nov 20. pii: 2716077. doi: 10.7326/M17-1987.
    PubMed     Abstract available


  84. WHARAM JF, Lu CY, Zhang F, Callahan M, et al
    High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes.
    Ann Intern Med. 2018 Nov 20. pii: 2716078. doi: 10.7326/M17-3365.
    PubMed     Abstract available



  85. The Effect of High-Deductible Insurance Plans on Diabetes Care.
    Ann Intern Med. 2018 Nov 20. pii: 2716396. doi: 10.7326/P18-0018.
    PubMed    



  86. Comparing Diabetes Outcomes for Primary Care Provided by Physicians, Nurse Practitioners, and Physician Assistants.
    Ann Intern Med. 2018 Nov 20. pii: 2715823. doi: 10.7326/P18-0017.
    PubMed    


  87. TANNER M
    Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetes.
    Ann Intern Med. 2018;169:JC59.
    PubMed    


    September 2018
  88. CENTOR RM, Barry MJ
    Web Exclusive. Annals On Call - Oral Pharmacologic Therapy in Type 2 Diabetes: Choosing Therapy Wisely.
    Ann Intern Med. 2018;169:OC1.
    PubMed    


  89. HUMPHREY LL, Kansagara D, Qaseem A
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee.
    Ann Intern Med. 2018 Sep 4. pii: 2698899. doi: 10.7326/M18-1148.
    PubMed    


  90. ROGLIC G, Norris SL
    Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the
    Ann Intern Med. 2018 Sep 4. pii: 2698900. doi: 10.7326/M18-1149.
    PubMed     Abstract available


  91. CENTOR RM, Montori VM
    Web Exclusive. Annals On Call - Glycemic Control in Type 2 Diabetes: How Low Should We Go?
    Ann Intern Med. 2018;169:OC1.
    PubMed    


    August 2018

  92. Prevention of Diabetes With Mediterranean Diets.
    Ann Intern Med. 2018;169:271-272.
    PubMed    


  93. O'BRIEN R, Johnson E, Haneuse S, Coleman KJ, et al
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study.
    Ann Intern Med. 2018 Aug 7. pii: 2696493. doi: 10.7326/M17-2383.
    PubMed     Abstract available



  94. Outcomes of Bariatric Surgery in Patients With Diabetes.
    Ann Intern Med. 2018 Aug 7:1. doi: 10.7326/P18-0012.
    PubMed    


    July 2018
  95. EGAN AM, Montori VM
    Review: In adults with type 1 diabetes, SGLT-2 inhibitors reduce HbA1c but increase diabetic ketoacidosis.
    Ann Intern Med. 2018;169:JC3.
    PubMed    


  96. EGAN AM, Montori VM
    Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.
    Ann Intern Med. 2018;169:JC2.
    PubMed    


  97. MADENIDOU AV, Paschos P, Karagiannis T, Katsoula A, et al
    Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Ann Intern Med. 2018 Jul 10. pii: 2687651. doi: 10.7326/M18-0443.
    PubMed     Abstract available


    June 2018
  98. HIRSCH IB, Skyler JS
    Brief Commentary: Confusing Treatment Guidelines for Patients With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686099. doi: 10.7326/M18-1473.
    PubMed    


  99. SCHROEDER EB, Karter AJ
    Brief Commentary: Glycemic Targets for Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686097. doi: 10.7326/M18-1471.
    PubMed    


  100. MILES DRB
    Brief Commentary: Social Determinants of Health and Treatment Targets for Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686098. doi: 10.7326/M18-1472.
    PubMed    


  101. BURKE BV, Hedin S
    Brief Commentary: Laboratory Accuracy of Hemoglobin A1c Ranges and Treatment Targets for Patients With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686219. doi: 10.7326/M18-1482.
    PubMed    


  102. NARAYAN KMV, Jagannathan R
    Two in One: Diagnosing Type 2 Diabetes With Single-Sample Testing.
    Ann Intern Med. 2018 Jun 19. pii: 2685289. doi: 10.7326/M18-1477.
    PubMed    


  103. SELVIN E, Wang D, Lee AK, Coresh J, et al
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults.
    Ann Intern Med. 2018;168:900-901.
    PubMed    


  104. PETERSEN MP, Cefalu WT
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults.
    Ann Intern Med. 2018;168:900.
    PubMed    


  105. SELVIN E, Wang D, Matsushita K, Grams ME, et al
    Prognostic Implications of Single-Sample Confirmatory Testing for Undiagnosed Diabetes: A Prospective Cohort Study.
    Ann Intern Med. 2018 Jun 19. pii: 2684927. doi: 10.7326/M18-0091.
    PubMed     Abstract available


    May 2018
  106. MOIST L
    In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
    Ann Intern Med. 2018;168:JC52.
    PubMed    


    April 2018
  107. BEKIARI E, Karagiannis T, Tsapas A
    In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.
    Ann Intern Med. 2018;168:JC46.
    PubMed    


  108. VIGERSKY RA
    Continuous Glucose Monitoring in Patients With Type 2 Diabetes Receiving Insulin Injections.
    Ann Intern Med. 2018;168:528.
    PubMed    


  109. BECK RW, Riddlesworth TD
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:526-527.
    PubMed    


  110. HAAK T
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:525-526.
    PubMed    


  111. CHAMBERLAIN JJ, Johnson EL, Leal S, Rhinehart AS, et al
    Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
    Ann Intern Med. 2018 Apr 3. pii: 2677350. doi: 10.7326/M18-0222.
    PubMed     Abstract available


    March 2018
  112. GOEL A
    Intensive weight management in primary care improved weight loss and remission of type 2 diabetes.
    Ann Intern Med. 2018;168:JC30.
    PubMed    



  113. Hemoglobin A1c Targets for Nonpregnant Adults With Type 2 Diabetes Mellitus.
    Ann Intern Med. 2018 Mar 6. pii: 2674123. doi: 10.7326/P18-0003.
    PubMed    


  114. QASEEM A, Wilt TJ, Kansagara D, Horwitch C, et al
    Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians.
    Ann Intern Med. 2018 Mar 6. pii: 2674121. doi: 10.7326/M17-0939.
    PubMed     Abstract available


    January 2018
  115. GENERE N, Montori VM
    Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas.
    Ann Intern Med. 2018;168:JC8.
    PubMed    


    December 2017
  116. LIPSCOMBE LL
    Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
    Ann Intern Med. 2017;167:JC67.
    PubMed    


  117. LIPSCOMBE LL
    Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.
    Ann Intern Med. 2017;167:JC66.
    PubMed    



  118. Cost-Effectiveness of Individualized Management of Diabetes Among U.S. Adults.
    Ann Intern Med. 2017 Dec 12. pii: 2665905. doi: 10.7326/P17-9050.
    PubMed    


  119. LAITEERAPONG N, Cooper JM, Skandari MR, Clarke PM, et al
    Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Ann Intern Med. 2017 Dec 12. pii: 2665902. doi: 10.7326/M17-0537.
    PubMed     Abstract available


    October 2017
  120. SELVIN E, Wang D, Lee AK, Bergenstal RM, et al
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults by Using a Confirmatory Definition: A Cross-sectional Study.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1272.
    PubMed     Abstract available


  121. CONLIN PR, Colburn J, Aron D, Pries RM, et al
    Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1362.
    PubMed     Abstract available


  122. PETERS AL
    Rethinking Rates of Undiagnosed Diabetes: The Value of a Confirmatory Test.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-2576.
    PubMed    


  123. DASGUPTA I, Singh AK
    Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death.
    Ann Intern Med. 2017;167:JC47.
    PubMed    


  124. MURFF HJ
    Self-monitoring of blood glucose did not improve HbA1c or QoL at 1 year in non-insulin-treated type 2 diabetes.
    Ann Intern Med. 2017;167:JC46.
    PubMed    


    September 2017
  125. CHAMBERLAIN JJ, Kalyani RR, Leal S, Rhinehart AS, et al
    Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2017 Sep 12. doi: 10.7326/M17-1259.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: